Search company, investor...

Parabolic Drugs

parabolicdrugs.com

Founded Year

1996

Stage

IPO | IPO

Date of IPO

7/1/2010

Market Cap

0.35B

About Parabolic Drugs

Parabolic Drugs (NSE: PARABDRUGS) (BSE: 533211) is a research-based, pharmaceutical manufacturer and exporter of pharmaceutical products. It specializes in the development and manufacturing of active pharmaceuticals in the form of capsules, tablets, liquids, or other forms of dosage. The company was founded in 1996 and is based in Chandigarh, India.

Headquarters Location

S.C.O. 186-187, Second Floor, Sector 8-C IInd Floor, New Friends Colony

Chandigarh, 160008,

India

+91 1762308635

Missing: Parabolic Drugs's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Parabolic Drugs's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Parabolic Drugs News

Parabolic Drugs IPO Date, Price, GMP, Review, Details

Dec 30, 2022

Incorporated in 1996, Parabolic Drugs Limited is in the business of manufacturing Active Pharmaceutical Ingredients (API's) and API intermediates. APIs, also known as 'bulk drugs' or 'bulk actives' are the principal ingredient used in making finished dosages in the form of capsules, tablets, liquid, or other forms of dosage, with the addition of other APIs or inactive ingredients. Companies product portfolio comprises 42 APIs and 7 API intermediates which are marketed domestically and exported. Company own and operate two manufacturing facilities at Derabassi, Punjab, and Panchkula, Haryana. Company is in the process of setting up a custom synthesis and research and development (R&D) center at Barwala, Haryana. Company Financials What is Parabolic Drugs IPO? Parabolic Drugs IPO is a main-board IPO of 26,666,667 equity shares of the face value of ₹10 aggregating up to ₹200.00 Crores. The issue is priced at ₹75 to ₹85 per share. The minimum order quantity is 80 Shares. The IPO opens on Jun 14, 2010, and closes on Jun 17, 2010. Link Intime India Private Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE. When Parabolic Drugs IPO will open? The Parabolic Drugs IPO opens on Jun 14, 2010 and closes on Jun 17, 2010. What is the lot size of Parabolic Drugs IPO? Parabolic Drugs IPO lot size is 80 Shares and the minimum order quantity is . How to apply for Parabolic Drugs IPO? You can apply in Parabolic Drugs IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha , Upstox , 5Paisa , Edelweiss , ICICI Bank , HDFC Bank and SBI Bank . When Parabolic Drugs IPO allotment? The finalization of Basis of Allotment for Parabolic Drugs IPO will be done on [. ], and the allotted shares will be credited to your demat account by [.]. Check the Parabolic Drugs IPO allotment status . When is Parabolic Drugs IPO listing date? The Parabolic Drugs IPO listing date is on Thursday, July 1, 2010. Parabolic Drugs IPO Message Board

Parabolic Drugs Frequently Asked Questions (FAQ)

  • When was Parabolic Drugs founded?

    Parabolic Drugs was founded in 1996.

  • Where is Parabolic Drugs's headquarters?

    Parabolic Drugs's headquarters is located at S.C.O. 186-187, Second Floor, Sector 8-C, Chandigarh.

  • What is Parabolic Drugs's latest funding round?

    Parabolic Drugs's latest funding round is IPO.

  • Who are the investors of Parabolic Drugs?

    Investors of Parabolic Drugs include BTS Investment Advisors and Minivet.

  • Who are Parabolic Drugs's competitors?

    Competitors of Parabolic Drugs include OcuNexus Therapeutics, Micromet, Proteolix, Palkion, Speciality European Pharma and 10 more.

Compare Parabolic Drugs to Competitors

N
Naprogenix

Naprogenix has commercialized technology that aims to enable bio-prospecting (screening) of Kentucky native plants and mutant plants for molecules that could lead to plant-based medicines and natural insecticides. Founded in 2002, the company's current focus is on non-toxic insecticides, CNS-acting drugs and chemotherapeutic agents.

T
TruSource Technologies

TruSource Technologies, LLC has developed a patent-pending, anti-counterfeit sensor which it will market to pharmaceutical companies to protect their high-dollar, high-volume prescription drugs. These nano-composite sensors will generate additional revenues for pharmaceutical companies and protect their brand equity while protecting the heath and safety of consumers.

P
Psimei Pharmaceutical

Psimei Pharmaceuticals is developing boron-based drugs for applications in Photon Activation Therapy (PAT). This involves the use of standard radiotherapy to activate boron-based compounds which selectively target solid tumours. This results in an amplification of the therapeutic effect of conventional radiotherapy. Pre-clinical data for Psimei's lead product, PP200PAT, has demonstrated 90% true cure rates at 6 months in tumour models compared with 30% for conventional radiotherapy alone. It also enabled much shorter treatment regimes - days as opposed to weeks. This drug is being prepared for clinical development.

N
Novalar Pharmaceuticals

Novalar Pharmaceuticals develops a drug agent that is designed to reverse the effects of local anesthesia applied in dental procedures, thereby allowing patients to return to their daily activities without the speech impediments, lip biting, and difficulty in eating that can be caused by unintended soft-tissue anesthesia.

Can-Fite BioPharma Logo
Can-Fite BioPharma

Can-Fite BioPharma is a biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.

V
Virdante Pharmaceuticals

Virdante Pharmaceuticals is developing safer and more effective drugs for autoimmune and inflammatory diseases. The company's products incorporate a proprietary sialic switch technology to improve the anti-inflammatory properties of antibodies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.